Top

Published in:

Open Access 01-12-2012 | Research

The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)

Authors: Katharina Cima, James Twiss, Rudolf Speich, Stephen P McKenna, Ekkehard Grünig, Christian M Kähler, Nicola Ehlken, Ursula Treder, Sigrid R Crawford, Lars C Huber, Silvia Ulrich

Published in: Health and Quality of Life Outcomes | Issue 1/2012

Abstract

Background

Individuals with precapillary pulmonary hypertension (PH) experience severely impaired quality of life. A disease-specific outcome measure for PH, the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was developed and validated in the UK and subsequently adapted for use in additional countries. The aim of this study was to translate and assess the reliability and validity of the CAMPHOR for German-speaking populations.

Methods

Three main adaptation stages involved; translation (employing bilingual and lay panels), cognitive debriefing interviews with patients and validation (assessment of the adaptation’s psychometric properties). The psychometric evaluation included 107 patients with precapillary PH (60 females; age mean (standard deviation) 60 (15) years) from 3 centres in Austria, Germany and Switzerland.

Results

No major problems were found with the translation process with most items easily rendered into acceptable German. Participants in the cognitive debriefing interviews found the questionnaires relevant, comprehensive and easy to complete. Psychometric analyses showed that the adaptation was successful. The three CAMPHOR scales (symptoms, activity limitations and quality of life) had excellent test-retest reliability correlations (Symptoms = 0.91; Activity limitations = 0.91; QoL = 0.90) and internal consistency (Symptoms = 0.94; Activity limitations = 0.93; QoL = 0.94). Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of the CAMPHOR scales. The CAMPHOR adaptation also showed known group validity in its ability to distinguish between participants based on perceived general health, perceived disease severity, oxygen use and NYHA classification.

Conclusions

The CAMPHOR has been shown to be valid and reliable in the German population and is recommend for use in clinical practice.

Available only for authorised users

Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G, French Pulmonary Arterial Hypertension Network: Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36: 549–55. 10.1183/09031936.00057010CrossRefPubMed

Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ: Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management (REVEAL). Chest 2011, 141(2):363–373.CrossRefPubMed

Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong IJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J: Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008, 177: 1122–1127. 10.1164/rccm.200712-1841OCCrossRefPubMed

McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W: End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54: S97-S107. 10.1016/j.jacc.2009.04.007CrossRefPubMed

Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD: Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122: 164–172. 10.1161/CIRCULATIONAHA.109.898122CrossRefPubMed

Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117: 3010–3019. 10.1161/CIRCULATIONAHA.107.742510CrossRefPubMed

Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ: Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52: 2127–2134. 10.1016/j.jacc.2008.08.059CrossRefPubMed

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149: 521–530.CrossRefPubMed

Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ: Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119: 2894–2903. 10.1161/CIRCULATIONAHA.108.839274CrossRefPubMed

10.

Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347: 322–329. 10.1056/NEJMoa020204CrossRefPubMed

11.

Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW, for the Primary Pulmonary Hypertension Study Group: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334: 296–302. 10.1056/NEJM199602013340504CrossRefPubMed

12.

Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009, 135: 137–142. 10.1378/chest.07-0275CrossRefPubMed

13.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W: Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55: 1915–1922. 10.1016/j.jacc.2010.01.027CrossRefPubMed

14.

Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165: 800–804.CrossRefPubMed

15.

Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M: Measurement of Quality of Life in pulmonary hypertension and its significance. Eur Respir J 2006, 28: 808–815. 10.1183/09031936.06.00130405CrossRefPubMed

16.

Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD: Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011, 38: 608–616. 10.1183/09031936.00161410PubMedCentralCrossRefPubMed

17.

McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15: 103–115. 10.1007/s11136-005-3513-4CrossRefPubMed

18.

ATS: Statement:guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166: 111–117.CrossRef

19.

Wilsher M, Good N, Hopkins R, Young P, Milne D, Gibson A, Suppiah R, Ly J, Doughty R, Dalbeth N: The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology 2012, 17(4):647–652. May 10.1111/j.1440-1843.2012.02133.xCrossRefPubMed

20.

Goldman MD, Marrie RA, Cohen JA: Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008, 14(3):383–390. Apr 10.1177/1352458507082607CrossRefPubMed

21.

Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA: National Emphysema Treatment Trial Research Group. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003, 167: 1522–1527. 10.1164/rccm.200203-166OCCrossRefPubMed

22.

Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ: Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007, 26: 732–738. 10.1016/j.healun.2007.04.013CrossRefPubMed

23.

Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K, et al.: Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006, 97: 123–126. 10.1016/j.amjcard.2005.07.129CrossRefPubMed

24.

The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edition. Little, Brown & Co, Boston, Mass; 1994:253–256.

25.

Hunt SM, McEwen J: McKenna SP. Croom Helm, Measuring Health Status London; 1986.

26.

Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP: United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008, 27: 124–130. 10.1016/j.healun.2007.10.004CrossRefPubMed

27.

Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP: Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008, 15: 77–83.PubMedCentralPubMed

28.

Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E: Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011, 16: 1235–1240. 10.1111/j.1440-1843.2011.02030.xCrossRefPubMed

29.

McKenna SP, Hunt SM, Tennant A: The development of a patient-completed index of distress from the Nottingham Health Profile: A new measure for use in cost-utility studies. Br J Med Econ 1993, 6: 13–24.CrossRef

30.

McKenna SP, Ratcliffe J, Meads DM, Brazier JE: Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008, 6: 65. 10.1186/1477-7525-6-65PubMedCentralCrossRefPubMed

31.

Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J: The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008, 32: 1513–1519. 10.1183/09031936.00069708CrossRefPubMed

Title: The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)
Authors: Katharina Cima
James Twiss
Rudolf Speich
Stephen P McKenna
Ekkehard Grünig
Christian M Kähler
Nicola Ehlken
Ursula Treder
Sigrid R Crawford
Lars C Huber
Silvia Ulrich
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Health and Quality of Life Outcomes / Issue 1/2012
Electronic ISSN: 1477-7525
DOI: https://doi.org/10.1186/1477-7525-10-110

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Oral health-related quality of life in an aging Canadian population

Development and validation of the self-management profile for type 2 diabetes (SMP-T2D)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran

Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients

Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population

Assessment of cardiometabolic risk among shift workers in Hungary